Related references
Note: Only part of the references are listed.Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models
Sascha Troschke-Meurer et al.
CANCERS (2023)
Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
Aleksandra Wieczorek et al.
FRONTIERS IN ONCOLOGY (2023)
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
Kelly C. Goldsmith et al.
NATURE MEDICINE (2023)
Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report
Jaume Mora et al.
CANCERS (2023)
Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events
Jaume Mora et al.
CANCER REPORTS (2023)
Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A
Wayne L. Furman et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group
Ami Desai et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
Nur Olgun et al.
FRONTIERS IN ONCOLOGY (2022)
Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: Outcomes from the first prespecified analyses of the Pivotal 201 Trial
J. Mora et al.
ANNALS OF ONCOLOGY (2022)
Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group
Rajen Mody et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children
Veronique Minard-Colin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG)
Navin Pinto et al.
EUROPEAN JOURNAL OF CANCER (2019)
Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results of HITS pilot/phase II study.
Jaume Mora et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials
Ruth Ladenstein et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study
Loredana Amoroso et al.
CANCER RESEARCH AND TREATMENT (2018)
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials
Lucas Moreno et al.
PEDIATRIC BLOOD & CANCER (2017)
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting
Julie R. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Irinotecan-temozolomide with temsirolimus or dinutuximab Crosstafark in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
Rajen Mody et al.
LANCET ONCOLOGY (2017)
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials
Wendy B. London et al.
CANCER (2017)
131I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study
Gregory A. Yanik et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7)
J. Mora et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2015)
Different outcomes for relapsed versus refractory neuroblastoma after therapy with 131I-metaiodobenzylguanidine (131I-MIBG)
Margaret J. Zhou et al.
EUROPEAN JOURNAL OF CANCER (2015)
Striking Dichotomy in Outcome of MYCN-Amplified Neuroblastoma in the Contemporary Era
Brian H. Kushner et al.
CANCER (2014)
Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children's Oncology Group
Gregory A. Yanik et al.
JOURNAL OF NUCLEAR MEDICINE (2013)
Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study
Rochelle Bagatell et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study
Julie R. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase II Randomized Comparison of Topotecan Plus Cyclophosphamide Versus Topotecan Alone in Children With Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Study
Wendy B. London et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
New Therapeutic Targets for the Treatment of High-Risk Neuroblastoma
Lars M. Wagner et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastorna >1 year of age on a high-risk treatment protocol:: Results of the German Neuroblastoma Trial NB97
Matthias Schmidt et al.
EUROPEAN JOURNAL OF CANCER (2008)
High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial
Andrew D. J. Pearson et al.
LANCET ONCOLOGY (2008)
Phase II study of temozolomide in relapsed or refractory high-risk neuroblastoma: A Joint Societe' Francaise des Cancers de l'Enfant and United Kingdom Children Cancer Study Group-New Agents Group Study
Herve Rubie et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Irinotecan plus temozolomide for relapsed or refractory neuroblastoma
Brian H. Kushner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Five-day courses of irinotecan as palliative therapy for patients with neuroblastoma
BH Kushner et al.
CANCER (2005)
Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol
D Valteau-Couanet et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma
HM Katzenstein et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma
BH Kushner et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma
KK Matthay et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Induction chemotherapy in metastatic neuroblastoma - does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC)
CR Pinkerton et al.
EUROPEAN JOURNAL OF CANCER (2000)
Share Paper
